By Jon Shepheard - Advisory Editor2025-03-13T09:00:08
A commonly prescribed diabetes medication could significantly enhance long-term recovery prospects for cancer patients by reducing their risk of heart failure, a new study from the University of East Anglia (UEA) reveals.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T09:00:00Z
2026-07-03T09:00:00Z
2026-06-29T06:49:00
Contributor Laura Alvarez, By Drug Target Review
2025-06-02T10:00:00
Contributor Professor Stefan Trapp, By Drug Target Review
2026-05-26T09:05:00
Contributor Thomas Clozel M.D., By Drug Target Review
2026-06-04T07:05:00
Author Graham Craig
2024-01-10T08:56:17
Sponsored by Leica Microsystems
2026-06-30T14:00:00
Sponsored by Analytik Jena GmbH + Co. KG
Site powered by Webvision Cloud